Twist Bioscience (NASDAQ:TWST) Issues Quarterly Earnings Results

Twist Bioscience (NASDAQ:TWST) issued its earnings results on Monday. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09, Zacks reports. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. Twist Bioscience updated its Q2 2025 guidance to EPS and its FY 2025 guidance to EPS.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $52.37 on Monday. The company’s 50 day moving average price is $48.39 and its two-hundred day moving average price is $46.23. Twist Bioscience has a 52 week low of $27.41 and a 52 week high of $60.90.

Insiders Place Their Bets

In other news, CFO Adam Laponis sold 5,886 shares of Twist Bioscience stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $43.26, for a total value of $254,628.36. Following the sale, the chief financial officer now directly owns 110,096 shares in the company, valued at $4,762,752.96. This trade represents a 5.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Emily M. Leproust sold 14,334 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the completion of the sale, the chief executive officer now owns 589,552 shares in the company, valued at $26,294,019.20. This trade represents a 2.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 80,407 shares of company stock worth $3,757,443. Company insiders own 3.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Barclays reduced their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Leerink Partners raised their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Scotiabank raised their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 19th. Wolfe Research began coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Finally, TD Cowen reissued a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.